259 related articles for article (PubMed ID: 25088418)
1. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.
Rigamonti N; Kadioglu E; Keklikoglou I; Wyser Rmili C; Leow CC; De Palma M
Cell Rep; 2014 Aug; 8(3):696-706. PubMed ID: 25088418
[TBL] [Abstract][Full Text] [Related]
2. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.
Daly C; Eichten A; Castanaro C; Pasnikowski E; Adler A; Lalani AS; Papadopoulos N; Kyle AH; Minchinton AI; Yancopoulos GD; Thurston G
Cancer Res; 2013 Jan; 73(1):108-18. PubMed ID: 23149917
[TBL] [Abstract][Full Text] [Related]
3. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Allen E; Walters IB; Hanahan D
Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
[TBL] [Abstract][Full Text] [Related]
4. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis.
De Palma M; Naldini L
Clin Cancer Res; 2011 Aug; 17(16):5226-32. PubMed ID: 21576085
[TBL] [Abstract][Full Text] [Related]
5. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.
Mazzieri R; Pucci F; Moi D; Zonari E; Ranghetti A; Berti A; Politi LS; Gentner B; Brown JL; Naldini L; De Palma M
Cancer Cell; 2011 Apr; 19(4):512-26. PubMed ID: 21481792
[TBL] [Abstract][Full Text] [Related]
6. Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.
Park JS; Kim IK; Han S; Park I; Kim C; Bae J; Oh SJ; Lee S; Kim JH; Woo DC; He Y; Augustin HG; Kim I; Lee D; Koh GY
Cancer Cell; 2016 Dec; 30(6):953-967. PubMed ID: 27960088
[TBL] [Abstract][Full Text] [Related]
7. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.
Schmittnaegel M; Rigamonti N; Kadioglu E; Cassará A; Wyser Rmili C; Kiialainen A; Kienast Y; Mueller HJ; Ooi CH; Laoui D; De Palma M
Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404865
[TBL] [Abstract][Full Text] [Related]
8. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.
Jung K; Heishi T; Khan OF; Kowalski PS; Incio J; Rahbari NN; Chung E; Clark JW; Willett CG; Luster AD; Yun SH; Langer R; Anderson DG; Padera TP; Jain RK; Fukumura D
J Clin Invest; 2017 Aug; 127(8):3039-3051. PubMed ID: 28691930
[TBL] [Abstract][Full Text] [Related]
9. Periostin Limits Tumor Response to VEGFA Inhibition.
Keklikoglou I; Kadioglu E; Bissinger S; Langlois B; Bellotti A; Orend G; Ries CH; De Palma M
Cell Rep; 2018 Mar; 22(10):2530-2540. PubMed ID: 29514082
[TBL] [Abstract][Full Text] [Related]
10. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
12. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
13. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Allen E; Jabouille A; Rivera LB; Lodewijckx I; Missiaen R; Steri V; Feyen K; Tawney J; Hanahan D; Michael IP; Bergers G
Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404866
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
Casanovas O; Hicklin DJ; Bergers G; Hanahan D
Cancer Cell; 2005 Oct; 8(4):299-309. PubMed ID: 16226705
[TBL] [Abstract][Full Text] [Related]
16. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
17. G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency.
Im JH; Tapmeier T; Balathasan L; Gal A; Yameen S; Hill S; Smart S; Noterdaeme O; Kelly M; Brady M; Fu W; Kruse K; Bernhard EJ; Augustin HG; Muschel RJ
Int J Cancer; 2013 Jan; 132(2):315-26. PubMed ID: 22699974
[TBL] [Abstract][Full Text] [Related]
18. Synergistic actions of blocking angiopoietin-2 and tumor necrosis factor-α in suppressing remodeling of blood vessels and lymphatics in airway inflammation.
Le CT; Laidlaw G; Morehouse CA; Naiman B; Brohawn P; Mustelin T; Connor JR; McDonald DM
Am J Pathol; 2015 Nov; 185(11):2949-68. PubMed ID: 26348576
[TBL] [Abstract][Full Text] [Related]
19. A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis.
Rennel ES; Regula JT; Harper SJ; Thomas M; Klein C; Bates DO
Microcirculation; 2011 Oct; 18(7):598-607. PubMed ID: 21851472
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
